乳腺癌血浆纤维蛋白原及外周血参数的相关分析

Clinical value on fibrinogen and peripheric hematologic parameters in patients with breast cancer

目的:探讨乳腺癌患者血浆纤维蛋白原和外周血参数的临床意义和预后价值。方法:检测65例治疗前乳腺癌患者和65例正常对照的纤维蛋白原(FIB)水平,c-erbB-2、ER、PR表达情况,以及外周血相关参数。结果:65例乳腺癌组的FIB、白细胞(whitebloodcell,WBC)计数和血小板(platelet,PLT)计数分别为:3.29±0.83g/L、6.47±1.68×109/L、261.1±76.62×109/L,均高于正常对照组(2.47±0.92g/L、5.76±1.08×109/L、204.2±54.8×109/L)(P<0.05)。在乳腺癌组,随着临床分期的增高,患者FIB和PLT逐渐增高(rFIB=0.269,P=0.037;rPLT=0.416,P=0.001)。结论:初诊时纤维蛋白原水平和血小板计数能反映乳腺癌患者体内异常的凝血状态,并与临床分期相关,为临床提供影像学和病理学依据以外的血液学依据,可作为乳腺癌诊治和预后的指标。

Objective：To investigate the clinical significance and prognostic value of plasma fibrinogen and peripheric hematologic parameters in patients with breast cancer. Methods： Levels of fibrinogen, c - erb - B2, ER, PR and correlative hematologic parameters were detected in 65 pretreatment patients with breast cancer and in 65 healthy women. Results： Fibrinogen,white blood cell counts and platelet counts in the group of breast cnacer were significantly higher than those in the group of healthy women （3.29 ±0.83 g/L,6.47 ± 1.68 × 10^9/L,261.1 ±76.62 × 10^9/L, vs 2.47 ± 0.92 g/L,5.76 ± 1.08 × 10^9/L,204.2 ± 54.8 × 10^9/L,respectively,P 〈 0.05 ）. There was significant rise on levels of fibrinogen and platelet counts while patients were in higher clinical stage （ rFIB = 0. 269,P = 0. 037 ; rPLT = 0. 416,P = 0.001 ）. Conclusion： Levels of fibrinogen and platelet counts of pretreatment patients with breast cancer can reflect abnormal blood coagulation condition and associate with clinical stage. The parameters provide hematological evidence besides evidence of images and pathology. They are indicators of treatment, diagnosis in breast cancer.